Comments

CERo Therapeutics Hldgs

CERONASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

Why is it moving?

CERo Therapeutics shares are trading higher after the company received FDA clearance for its investigational new drug application to initiate a Phase 1 clinical trial of CER-1236 for acute myelogenous leukemia.

CERo Therapeutics Hldgs (CERO) Forecast News Earnings CERo Therapeutics Hldgs (CERO) Options Guidance Dividends

Analyst Ratings

Insider Trades Short Interest

CERo Therapeutics Hldgs (NASDAQ:CERO) Stock, Analyst Ratings, Price Targets, Forecasts

Quote.Descriptions.analyst-ratings.

Analyst Ratings for CERo Therapeutics Hldgs

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for CERo Therapeutics Hldgs (CERO) stock?

A

There is no price target for CERo Therapeutics Hldgs

Q

What is the most recent analyst rating for CERo Therapeutics Hldgs (CERO)?

A

There is no analyst for CERo Therapeutics Hldgs

Q

When was the last upgrade for CERo Therapeutics Hldgs (CERO)?

A

There is no last upgrade for CERo Therapeutics Hldgs

Q

When was the last downgrade for CERo Therapeutics Hldgs (CERO)?

A

There is no last downgrade for CERo Therapeutics Hldgs.

Q

When is the next analyst rating going to be posted or updated for CERo Therapeutics Hldgs (CERO)?

A

There is no next analyst rating for CERo Therapeutics Hldgs.

Q

Is the Analyst Rating CERo Therapeutics Hldgs (CERO) correct?

A

There is no next analyst rating for CERo Therapeutics Hldgs.

Browse analyst ratings and price targets on all stocks.

People Also Watch